Bisphosphonates in the management of postmenopausal osteoporosis – optimizing efficacy in clinical practice
Oliver Bock, Dieter FelsenbergCenter for Muscle and Bone Research, Campus Benjamin Franklin, Charité – University Medicine Berlin, Berlin, GermanyAbstract: Nitrogen-containing bisphosphonates are potent inhibitors of osteoclastic bone resorption. With their individually proven e...
Guardado en:
Autores principales: | Oliver Bock, Dieter Felsenberg |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2008
|
Materias: | |
Acceso en línea: | https://doaj.org/article/bc4019bc29de4d76b9e1c2a471fbcaca |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Optimizing dosing frequencies for bisphosphonates in the management of postmenopausal osteoporosis: patient considerations
por: John Sunyecz
Publicado: (2008) -
Full length parathyroid hormone (1–84) in the treatment of osteoporosis in postmenopausal women
por: Esteban Jódar-Gimeno
Publicado: (2007) -
The differential effects of bisphosphonates, SERMS (selective estrogen receptor modulators), and parathyroid hormone on bone remodeling in osteoporosis
por: Silvia Migliaccio, et al.
Publicado: (2007) -
Quarterly intravenous injection of ibandronate to treat osteoporosis in postmenopausal women
por: Philip Sambrook
Publicado: (2007) -
Risedronate once monthly: a potential new regimen for the treatment of postmenopausal osteoporosis
por: María J Moro-Álvarez, et al.
Publicado: (2008)